scispace - formally typeset
Journal ArticleDOI

Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.

Matteo Monami, +2 more
- 01 Oct 2013 - 
- Vol. 15, Iss: 10, pp 938-953
Reads0
Chats0
TLDR
Cardiovascular safety of sulfonylurea has been questioned by some authors and all available data on this issue from randomized trials is collected.
Abstract
Aim Cardiovascular safety of sulfonylurea has been questioned by some authors. This article aims at collecting all available data on this issue from randomized trials. Methods A meta-analysis was performed including all trials with a duration of at least 6 months, comparing a sulfonylurea with a non-sulfonylurea agent in type 2 diabetes. Major cardiovascular events (MACE) and mortality were retrieved and combined to calculate Mantel-Haenzel odds ratio (MH-OR). Results Of the 115 selected trials, 62 reported information on MACE, and 30 reported at least one event. MH-OR for sulfonylurea was 1.08 [0.86–1.36], p = 0.52 (1.85 [1.20–2.87], p = 0.005, in the five trials vs. DPP4 inhibitors, no significant differences vs. other comparators). The MH-OR for myocardial infarction and stroke was 0.88 [0.75–1.04], p = 0.13 and 1.28 [1.03–1.60], p = 0.026, respectively. Mortality was significantly increased with sulfonylureas (MH-OR: 1.22 [1.01–1.49], p = 0.047). Conclusions In type 2 diabetes, the use of sulfonylureas is associated with increased mortality and a higher risk of stroke, whereas the overall incidence of MACE appears to be unaffected. Significant differences in cardiovascular risk could be present in direct comparisons with specific classes of glucose-lowering agents, such as DPP4 inhibitors, but this hypothesis needs to be confirmed in long-term cardiovascular outcomes trials. The results of this meta-analysis need to be interpreted with caution, mainly because of limitations in trial quality and under-reporting of information on cardiovascular events and mortality. However, the cardiovascular safety of sulfonylureas cannot be considered established unless it is evaluated in long-term cardiovascular outcomes trials.

read more

Citations
More filters
Journal ArticleDOI

Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip.

TL;DR: A review of cardiovascular outcome trials with glucose-lowering drugs used in type 2 diabetes mellitus suggests the possible contribution to the incretin cardiovascular effects of a direct cardiac action of GLP-1 metabolites through GLp-1 receptor-independent pathways, and of DPP4 substrates other than GLP -1.
Journal ArticleDOI

Effects of sulfonylureas on lipids in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.

TL;DR: A meta‐analysis of randomized controlled trials to assess the effects of SUs on the level of lipids in patients with type 2 diabetes mellitus found that dyslipidemia was potentially associated with anti‐diabetic medications of sulfonylureas.
Journal ArticleDOI

Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.

TL;DR: Based on recent CVOTs and guideline updates, the choice of add-on to metformin therapy for patients with T2DM and established CV disease should be a sodium-glucose co-transporter-2 inhibitor or a glucagon-like peptide-1 agonist with proven CV benefit.
Journal ArticleDOI

Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.

TL;DR: In this paper, the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors compared with other antihyperglycaemic agents (AHAs) in large and unselected populations of the Lombardy and Apulia regions in Italy were examined using conditional Cox models.
Journal ArticleDOI

Sulfonylurea and neuroprotection: The bright side of the moon.

TL;DR: Sulfonylurea drugs mainly glibenclamide is effective at a low dose in the management of cerebral stroke and could be a contestant with corticosteroid in controlling brain edema.
References
More filters
Journal ArticleDOI

Bias in meta-analysis detected by a simple, graphical test

TL;DR: Funnel plots, plots of the trials' effect estimates against sample size, are skewed and asymmetrical in the presence of publication bias and other biases Funnel plot asymmetry, measured by regression analysis, predicts discordance of results when meta-analyses are compared with single large trials.
Journal ArticleDOI

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

TL;DR: A structured summary is provided including, as applicable, background, objectives, data sources, study eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings.
Journal ArticleDOI

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

TL;DR: PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) is introduced, an update of the QUOROM guidelines for reporting systematic reviews and meta-analyses.
Journal Article

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

R C Turner, +398 more
- 12 Sep 1998 - 
TL;DR: In this article, the effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
Journal ArticleDOI

Assessing the quality of reports of randomized clinical trials : is blinding necessary?

TL;DR: An instrument to assess the quality of reports of randomized clinical trials (RCTs) in pain research is described and its use to determine the effect of rater blinding on the assessments of quality is described.
Related Papers (5)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

R C Turner, +398 more
- 12 Sep 1998 -